Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Kronos Bio Inc (NASDAQ: KRON) closed the day trading at $0.71 down -19.98% from the previous closing price of $0.89. In other words, the price has decreased by -$19.98 from its previous closing price. On the day, 9.0 million shares were traded. KRON stock price reached its highest trading level at $0.74 during the session, while it also had its lowest trading level at $0.67.
Ratios:
For a better understanding of KRON, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.54 and its Current Ratio is at 7.54. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.25.
On November 14, 2024, Piper Sandler Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $6 to $1.
On September 14, 2022, Berenberg started tracking the stock assigning a Buy rating and target price of $12.Berenberg initiated its Buy rating on September 14, 2022, with a $12 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 27 ’24 when BISCHOFBERGER NORBERT W bought 410,848 shares for $1.17 per share. The transaction valued at 478,843 led to the insider holds 10,597,468 shares of the business.
BISCHOFBERGER NORBERT W bought 204,670 shares of KRON for $254,957 on Jun 28 ’24. The PRESIDENT & CEO now owns 10,802,138 shares after completing the transaction at $1.25 per share. On Jun 10 ’24, another insider, BISCHOFBERGER NORBERT W, who serves as the PRESIDENT & CEO of the company, bought 1,378,901 shares for $0.88 each. As a result, the insider paid 1,208,469 and bolstered with 5,749,395 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KRON now has a Market Capitalization of 43556396 and an Enterprise Value of -43965592. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.42 while its Price-to-Book (P/B) ratio in mrq is 0.49. Its current Enterprise Value per Revenue stands at -4.464 whereas that against EBITDA is 0.712.
Stock Price History:
The Beta on a monthly basis for KRON is 1.76, which has changed by -0.3 over the last 52 weeks, in comparison to a change of 0.092895746 over the same period for the S&P500. Over the past 52 weeks, KRON has reached a high of $1.60, while it has fallen to a 52-week low of $0.69. The 50-Day Moving Average of the stock is -19.20%, while the 200-Day Moving Average is calculated to be -26.69%.
Shares Statistics:
Over the past 3-months, KRON traded about 151.82K shares per day on average, while over the past 10 days, KRON traded about 979710 shares per day. A total of 60.46M shares are outstanding, with a floating share count of 39.23M. Insiders hold about 35.66% of the company’s shares, while institutions hold 23.35% stake in the company. Shares short for KRON as of 1744675200 were 669437 with a Short Ratio of 4.41, compared to 1741910400 on 747980. Therefore, it implies a Short% of Shares Outstanding of 669437 and a Short% of Float of 1.4400001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
